Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a substituted benzimidazole proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+-ATPase enzyme system at the secretory surface of the gastric parietal cell.
## Primary Indications
* Erosive esophagitis associated with GERD.
* Maintenance of healing of erosive esophagitis.
* Pathological hypersecretory conditions including Zollinger-Ellison (ZE) syndrome.
* Short-term treatment of GERD symptoms.
## Adult Dosing
* **Erosive Esophagitis Treatment:** 40 mg orally or IV once daily for up to 8 weeks.
* **Maintenance:** 40 mg orally once daily.
* **Hypersecretory Conditions (ZE syndrome):** Start at 40 mg twice daily. Titrate upward based on patient need; daily doses up to 240 mg have been administered. Doses >80 mg/day should be divided.
## Pediatric Dosing
* **GERD (Erosive Esophagitis) ≥5 years:**
* 15 kg to <40 kg: 20 mg once daily for up to 8 weeks.
* ≥40 kg: 40 mg once daily for up to 8 weeks.
* *Note: Safety/efficacy beyond 8 weeks has not been established in pediatric populations.*
## Dose Adjustments
* **Renal Impairment:** No dosage adjustment necessary.
* **Hepatic Impairment:** No specific dosage adjustment required, but use caution in severe impairment; consider monitoring liver enzymes if long-term therapy is required.
* **Elderly:** No dosage adjustment necessary.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
* Concomitant use with rilpivirine-containing products (due to reduced rilpivirine absorption).
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, flatulence.
* **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), hypomagnesemia, vitamin B12 deficiency (with long-term use), acute interstitial nephritis, cutaneous lupus erythematosus, and systemic lupus erythematosus.
## Key Drug Interactions
* **pH-dependent drugs:** May decrease absorption of ketoconazole, atazanavir, nelfinavir, and iron salts.
* **Methotrexate:** PPIs may increase serum concentrations, potentially increasing toxicity (use caution, especially in high-dose therapy).
* **Clopidogrel:** Potential reduced antiplatelet effect; clinical significance remains controversial, but alternatives (e.g., rabeprazole) may be considered if interaction is a concern.
## Monitoring
* Monitor for signs of *C. difficile* diarrhea (fever, persistent diarrhea).
* In long-term use: Monitor magnesium levels and B12 levels.
* Baseline and period LFTs if signs of liver dysfunction occur.
## Clinical Pearls
* **Administration:** Tablets may be taken without regard to meals. If using oral suspension, administer 30 minutes before a meal. IV pantoprazole should be administered as a 15-minute infusion or a 2-minute bolus.
* **Tapering:** Long-term PPI use can cause rebound acid hypersecretion upon discontinuation; consider a gradual taper for chronic users.
* **Safety:** PPIs are associated with increased risk of fractures (osteoporosis-related); ensure adequate calcium and vitamin D intake in high-risk patients.
***
**Disclaimer:** This information is for educational purposes only. Always verify drug dosages, contraindications, and interaction data against current clinical references (e.g., Lexicomp, UpToDate) and institutional protocols before prescribing or administering medication.
